ERBB2 and gastroesophageal junction adenocarcinoma: The median PFS and OS were 4.1 months (95% CI: 3.7–4.9 months) and 7.9 months (95% CI: 6.7–9.9 months) for RC48 as third-line or subsequent treatment for HER2-positive advanced gastric/GEJ adenocarcinoma (Peng et al., 2021).